• Open Access

Serum Thymidine Kinase Activity in Dogs with Malignant Lymphoma: A Potent Marker for Prognosis and Monitoring the Disease

Authors

  • Henrik von Euler,

    Corresponding author
    1. Faculty of Veterinary Medicine and Animal Science, Department of Small Animal Clinical Sciences, Swedish University of Agricultural Sciences (SLU), S-750 07 Uppsala, Sweden
      Faculty of Veterinary Medicine and Animal Science, Department of Small Animal Clinical Sciences, Swedish University of Agricultural Sciences (SLU), P.O. Box 7037, S-750 07 Uppsala, Sweden; e-mail: henrik.von.euler@kirmed.slu.se.
    Search for more papers by this author
  • Roland Einarsson,

    1. DiaSorin AB, Bromma, Sweden
    Search for more papers by this author
  • Ulf Olsson,

    1. Department of Biometry and Informatics, Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    Search for more papers by this author
  • Anne-Sofie Lagerstedt,

    1. Faculty of Veterinary Medicine and Animal Science, Department of Small Animal Clinical Sciences, Swedish University of Agricultural Sciences (SLU), S-750 07 Uppsala, Sweden
    Search for more papers by this author
  • Staffan Eriksson

    1. Faculty of Veterinary Medicine and Animal Science, Department of Molecular Biosciences, Biomedicinska Centrum (BMC), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    Search for more papers by this author

  • Parts of the work were presented as an oral scientific research communication at the ECVIM-CA Congress, Uppsala, Sweden, 2003.

Faculty of Veterinary Medicine and Animal Science, Department of Small Animal Clinical Sciences, Swedish University of Agricultural Sciences (SLU), P.O. Box 7037, S-750 07 Uppsala, Sweden; e-mail: henrik.von.euler@kirmed.slu.se.

Abstract

Serum thymidine kinase (sTK) activity was evaluated as a tumor marker for canine malignant lymphoma (ML). The objective was to investigate if sTK, as in humans, could be used as a prognostic marker for survival time in dogs with ML and if sTK could identify early signs of progression of disease in treated dogs. Serum samples from 52 dogs with ML were tested for initial TK activity. Samples from 21 normal dogs and 25 dogs with nonhematologic neoplasms were used for comparison. Forty-four dogs with ML were treated. Serum TK activity was measured in treated dogs before each treatment and every 4 weeks thereafter until relapse. Dogs with ML had 2–180 times higher TK activity (TK 5–900 U/L) than normal dogs (TK <7 U/L) based on the mean + 2 standard deviations. In the group of other neoplasms, only 2 dogs had a moderate increase (6.4 and 7.5 U/L) compared with the controls. Mean sTK activities in the dogs with ML that had gone into complete remission (CR) were not significantly different from activities in healthy controls (P= .68). Mean sTK at least 3 weeks before and at the time of relapse was significantly higher than activity measured at CR (P < .0001). Dogs with ML that initially had sTK >30 U/L had significantly shorter survival times (P < .0001). Furthermore, sTK activity reflected the clinical staging of ML. Measuring sTK can be used as a powerful objective tumor marker for prognosis and for predicting relapse before recurrence of clinically detectable disease in dogs with ML undergoing chemotherapy.

Ancillary